In its 2008 review, sanofi announced that it would expand its branded generics program. Given this, my guess on an [Lovenox] AG is > 50%
“Branded generics” and “authorized generics” are two separate things that have nothing to do with one another.
Branded generics are non-substitutable branded knockoffs of off-patent drugs in countries that restrict or don’t permit automatic substitution of a generic for a branded product; such countries include Germany, Japan, and most “emerging markets.”
Authorized generics are unbranded substitutable generics that are made or licensed by the manufacturer of the originally patented branded drug; AG’s exist only in countries that do permit automatic substitution of a generic drug for a branded one, notably the US.
When Sanofi says they are looking to expand their branded generics business, they are not talking about the US market and they are not talking about Lovenox.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”